Extracorporeal Light-chain Elimination in Myeloma with Simple Medium Cutoff Membrane Hemodialysis: a Retrospective Cohort Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Sep 25

PMID 37746285

Authors

Christian W Schaaf

Matthias C Braunisch

Christopher Holzmann-Littig

Frederick Pfister

Liya Hannemann

Renate I Hausinger

Mareike Verbeek

Christoph Schmaderer

Lutz Renders

Uwe Heemann

Claudius Kuchle

Affiliations

Soon will be listed here.

Abstract

Background: We determined the efficacy of free light chain (FLC) removal by regular dialysis equipment (high-flux filtration) with medium cutoff (MCO) membrane hemodialysis (HD) as an adjuvant treatment to standard chemotherapy for patients with acute kidney injury complicating multiple myeloma (MM) and its impact on further dialysis dependency.

Methods: Sixty patients with acute dialysis-dependent renal failure secondary to MM were treated with MCO-HD (55 patients) or HCO (high cutoff)-HD (5 patients) as a control. FLC serum concentration, total protein, immunoglobulins, and LDH were measured throughout the dialysis therapy. The kidney function of the patients was followed up for 1 year.

Results: The median age was 69 years; 25 female and 35 male patients were enrolled. HD significantly reduced FLC kappa levels in the MCO/HCO group by 58%/84% (MCO/HCO group; < 0.05) and FLC lambda by 39%/33% (MCO/HCO group; < 0.05). Single HD data (MCO) showed a relative reduction of 70% in kappa and 37% in lambda FLC concentration, as expected by the different sizes of the light chains. Renal function improved significantly and continuously from starting creatinine 5.7/3.8 mg/dl (MCO/HCO group) before HD to 1.4/2.0 mg/dl (MCO/HCO group; < 0.001) after 1 year. No significant alteration of total protein, immunoglobulins, and LDH concentrations by HD (HCO and MCO group) was observed. After 1 year, 37 of 60 patients were alive and 34 of them were off dialysis.

Conclusion: FLC elimination with MCO-HD is effective, technically easy, and less cost-intensive as compared with HCO-HD. Kidney function recovery in MM patients is achievable.

References

Hutchison C, Cockwell P, Reid S, Chandler K, Mead G, Harrison J . Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007; 18(3):886-95. DOI: 10.1681/ASN.2006080821. View

Clark W, Stewart A, Rock G, Sternbach M, Sutton D, Barrett B . Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005; 143(11):777-84. DOI: 10.7326/0003-4819-143-11-200512060-00005. View

Dimopoulos M, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S . Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010; 28(33):4976-84. DOI: 10.1200/JCO.2010.30.8791. View

Ramos Terrades N, Senin A, Azancot M, Gironella M, Toapanta N, Bermejo S . Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view. Clin Kidney J. 2023; 16(6):1014-1021. PMC: 10229297. DOI: 10.1093/ckj/sfad022. View

Tanner G, Evan A . Glomerular and proximal tubular morphology after single nephron obstruction. Kidney Int. 1989; 36(6):1050-60. DOI: 10.1038/ki.1989.300. View

Hutchison C, Bradwell A, Cook M, Basnayake K, Basu S, Harding S . Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009; 4(4):745-54. PMC: 2666427. DOI: 10.2215/CJN.04590908. View

Gerth H, Pohlen M, Gorlich D, Tholking G, Kropff M, Berdel W . Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study. PLoS One. 2016; 11(5):e0154993. PMC: 4859546. DOI: 10.1371/journal.pone.0154993. View

Bridoux F, Leung N, Belmouaz M, Royal V, Ronco P, Nasr S . Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021; 99(3):570-580. DOI: 10.1016/j.kint.2020.11.010. View

Finkel K, Gallieni M . Extracorporeal Removal of Light Chains: New Data and Continued Controversies. Clin J Am Soc Nephrol. 2018; 13(11):1753-1754. PMC: 6237060. DOI: 10.2215/CJN.05100418. View

10.

Haynes R, Read S, Collins G, Darby S, Winearls C . Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant. 2009; 25(2):419-26. DOI: 10.1093/ndt/gfp488. View

11.

Boschetti-de-Fierro A, Voigt M, Storr M, Krause B . MCO Membranes: Enhanced Selectivity in High-Flux Class. Sci Rep. 2015; 5:18448. PMC: 4680880. DOI: 10.1038/srep18448. View

12.

Sanders P, Booker B . Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest. 1992; 89(2):630-9. PMC: 442896. DOI: 10.1172/JCI115629. View

13.

Zannetti B, Zamagni E, Santostefano M, De Sanctis L, Tacchetti P, Mancini E . Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Am J Hematol. 2015; 90(7):647-52. DOI: 10.1002/ajh.24035. View

14.

Kaplan B, Livneh A, Sela B . Immunoglobulin free light chain dimers in human diseases. ScientificWorldJournal. 2011; 11:726-35. PMC: 5720091. DOI: 10.1100/tsw.2011.65. View

15.

Bachmann U, Schindler R, Storr M, Kahl A, Joerres A, Sturm I . Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma. NDT Plus. 2017; 1(2):106-108. PMC: 5477910. DOI: 10.1093/ndtplus/sfm053. View

16.

Hutchison C, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz M . Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011; 22(6):1129-36. PMC: 3103732. DOI: 10.1681/ASN.2010080857. View

17.

Curti A, Schwarz A, Trachsler J, Tomonaga Y, Ambuhl P . Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy. PLoS One. 2016; 11(7):e0159942. PMC: 4965060. DOI: 10.1371/journal.pone.0159942. View

18.

Cucchiari D, Reverter E, Blasco M, Molina-Andujar A, Carpio A, Sanz M . High cut-off membrane for in-vivo dialysis of free plasma hemoglobin in a patient with massive hemolysis. BMC Nephrol. 2018; 19(1):250. PMC: 6172805. DOI: 10.1186/s12882-018-1051-x. View

19.

Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Haring H . Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Ann Hematol. 2011; 91(5):729-735. DOI: 10.1007/s00277-011-1383-0. View

20.

Hutchison C, Heyne N, Airia P, Schindler R, Zickler D, Cook M . Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant. 2012; 27(10):3823-8. DOI: 10.1093/ndt/gfr773. View